文献速递免疫规划卫生政策与健康促进

成人破伤风-白喉疫苗接种:抗体长期持久性不依赖多克隆B细胞活化,白喉类毒素再接种缺陷应答与HLA-DRB1*01相关

Tetanus-diphtheria vaccination in adults: the long-term persistence of antibodies is not dependent on polyclonal B-cell activation and the defective response to diphtheria toxoid re-vaccination is associated to HLADRB1∗01.
PubMed 文献 · Vaccine · 2018-09-27

研究对接种过破伤风-白喉疫苗(Td)的意大利军人进行HLA分型,比较1次与多次Td加强者的抗体和T细胞应答,并设未接种Td组检验多克隆B细胞活化假说。结果显示抗体应答在1次加强组更高,抗破伤风抗体半衰期长于抗白喉,保护阈值以上持久性分别超过65年和20年;HLA-DRB1*01与白喉抗体应答缺陷相关,未发现多克隆B细胞活化维持抗白喉抗体。

要点

  • 抗破伤风和白喉抗体保护阈值(0.1 IU/ml)以上持久性分别估计超过65年和20年。
  • HLA-DRB1*01等位基因与白喉类毒素再接种后抗体应答缺陷显著相关。
  • 同时接种其他疫苗未观察到对Td应答的干扰,抗体与细胞应答间无相关性。

核心结论

  • Td疫苗接种诱导的血清保护持续时间较长,再接种间隔可能应长于10年。
  • 抗白喉抗体水平并非由多克隆B细胞活化维持,HLA-DRB1*01与白喉应答缺陷显著相关。

研究设计与样本

  • 对HLA分型的意大利军人评估Td疫苗的细胞和体液免疫应答,受试者接受多次同时接种。
  • 分组:1次Td加强组(group-1)、多于1次Td加强组(group-2)、接受多种疫苗但未接种Td组(group-3)。
  • 注册号NCT01807780。

主要发现

  • group-1基线抗体水平较低,但其对Td类毒素的抗体应答高于group-2。
  • 两组中抗破伤风类毒素抗体应答均高于抗白喉类毒素。
  • 未观察到抗体与细胞应答间的相关性,同时接种不同疫苗未干扰对Td的应答。
  • HLA-DRB1*01等位基因在接种后抗白喉抗体水平未能加倍者中频率显著更高。
  • 抗破伤风和白喉抗体半衰期经评估,保护阈值(0.1 IU/ml)以上持久性分别估计超过65年和20年。

关键数值与推荐

  • 保护阈值:0.1 IU/ml(抗破伤风和白喉抗体)。
  • 抗破伤风抗体保护阈值以上持久性估计超过65年,抗白喉超过20年。
  • 再接种间隔可能应长于10年。

临床怎么用

  • 成人Td再接种间隔可考虑长于10年,但需结合个体风险评估。
  • 对白喉疫苗应答缺陷者,可考虑HLA-DRB1*01检测以辅助评估。
  • 同时接种其他疫苗不干扰Td应答,无需因同时接种而推迟Td。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cellular and humoral immune responses to tetanus-diphtheria vaccine (Td) were assessed in human leukocyte antigen (HLA)-typed Italian military personnel who received multiple concomitant vaccines. Td-specific antibodies and T-lymphocytes were measured in individuals with one (group-1) and more than one (group-2) Td boosters. A third group (group-3), who received several vaccines, but not Td, was studied to verify the hypothesis of the polyclonal B-cell activation as mechanism for antibody persistence. The antibody response to Td toxoids was higher in group-1, who showed lower baseline antibody levels, than in group-2 subjects. The antibody response to tetanus was higher than to diphtheria toxoid in both groups. No correlation between antibody and cellular response, and no interference in the response to Td by co-administration of different vaccines were observed. HLA-DRB1∗01 allele was detected at significant higher frequency in subjects unable to double the baseline anti-diphtheria antibody levels after the vaccination. Anti-tetanus and diphtheria antibodies half-lives were assessed and the long-lasting persistence above the threshold for protection (0.1 IU/ml) was estimated in over 65 and 20 years, respectively. No significant increase of anti-diphtheria antibodies was observed in consequence of polyclonal B-cell activation. This study emphasizes the duration of Td vaccination-induced seroprotection, suggesting that re-vaccination should probably be performed at intervals longer than 10 years. No reciprocal interference by concomitantly administered vaccines has been observed. HLA-DRB1∗01 allele was significantly associated with anti-diphtheria defective response. Finally, this study does not confirm that anti-diphtheria antibody levels are maintained by polyclonal B-cell activation. Clinical trial registry: The study was registered with NCT01807780.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ferlito C, Biselli R, Mariotti S, et al. Tetanus-diphtheria vaccination in adults: the long-term persistence of antibodies is not dependent on polyclonal B-cell activation and the defective response to diphtheria toxoid re-vaccination is associated to HLADRB1∗01. Vaccine. 2018. PMID: 30269918. doi:10.1016/j.vaccine.2018.09.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。